Maxim Pharmaceuticals' Cancer Therapeutic Candidate Shows Promise

Maxim Pharmaceuticals, Inc., has made a significant breakthrough in cancer research with its proapoptotic cancer therapeutic candidate, MPC-6827. Developed in partnership with Myriad Genetics, Inc., MPC-6827 has shown promising results in preclinical studies, demonstrating better activity than current standard-of-care chemotherapy in xenograft models of various cancers. The compound's ability to induce apoptosis, or programmed cell death, in cancer cells, offers a new approach in the fight against cancer.

Key Takeaways:

• Maxim Pharmaceuticals' proprietary live cell high-throughput caspase-3 screening technology has identified a family of compounds, including MPC-6827, that induce apoptosis in cancer cells.
• Preclinical studies have shown MPC-6827's efficacy in treating breast, pancreas, colon, ovary, and prostate cancers, with better activity than current standard-of-care chemotherapy.
• Maxim's screening technology can adapt its assays for various tumor types and measure caspase activation in multiple cell types, allowing for the identification of potential drug candidates with selective therapeutic benefit.
• The company's high-throughput screening capabilities enable researchers to screen approximately 30,000 compounds per day, resulting in the identification of several families of compounds with promising preclinical efficacies.
• Four lead compounds, including MPC-6827, have progressed to clinical trials, with Maxim's screening technology playing a crucial role in their discovery.
• Maxim Pharmaceuticals has a diverse pipeline of therapeutic candidates for life-threatening cancers and liver diseases.

Statistics:

• 30,000 compounds screened per day using Maxim's high-throughput screening capabilities.
• 4 lead compounds, including MPC-6827, have progressed to clinical trials with proven preclinical efficacies.
• MPC-6827 has shown better activity than current standard-of-care chemotherapy in xenograft models of breast, pancreas, colon, ovary, and prostate cancers.
• Maxim's screening technology can adapt assays for various tumor types and measure caspase activation in multiple cell types.

Sources:

• Maxim Pharmaceuticals, Inc.
• Myriad Genetics, Inc.
• Health & Medicine Week editors via NewsRx.com & NewsRx.net, 2005.